XNAS · Healthcare · Biotechnology
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q1 2026 | -0.15 | -0.11 | +26.67% | $0 | ✅ Beat | +0.00% | -2.78% | — |
| 2026-03-05 | Q4 2025 | -0.18 | -0.14 | +22.22% | $0 | mixed | +1.74% | -3.86% | -6.14% |
| 2025-11-06 |
| Q3 2025 |
| -0.19 |
| -0.26 |
| -36.84% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-03-13 | Q4 2024 | -0.23 | -0.18 | +21.74% | $0 | ✅ Beat | -0.50% | -5.76% | -24.56% |
| 2024-11-07 | Q3 2024 | -0.22 | -0.23 | -4.55% | $0 | ❌ Miss | +0.65% | +2.90% | +13.87% |
| 2024-08-13 | Q2 2024 | -0.25 | -0.23 | +8.00% | $0 | ✅ Beat | +6.32% | +6.90% | +7.47% |
| 2024-05-02 | Q1 2024 | -0.24 | -0.23 | +4.17% | $235,000 | ✅ Beat | — | — | +0.00% |
| 2024-03-14 | Q4 2023 | -0.24 | -0.25 | -4.17% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.